Home
News
Create
Screeners
Insights
Dipna Pharmachem
6.
99
-0.17
(-2.37%)
Market Cap
₹18.35 Cr
PE Ratio
19.35
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.37%
1M
-11.96%
6M
-58.39%
1Y
-68.57%
5Y
-74.53%
View Company Insights
Latest news about Dipna Pharmachem
Dipna Pharmachem Approves Secretarial Auditor FY 2025-26
8 days ago
Dipna Pharmachem Limited has successfully concluded its postal ballot process for the appointment of M/s. Jay Pandya & Associates as Secretarial Auditor for the financial year 2025-26. The resolution received strong shareholder approval, with 99.77% of valid votes cast in favour. The e-voting process was conducted from April 23, 2026, to May 22, 2026, in compliance with SEBI regulations.
Dipna Pharmachem Postal Ballot for Secretarial Auditor Appointment FY 2025-26
Apr 22, 2026
Dipna Pharmachem Limited Submits SEBI Compliance Certificate for Q4FY26
Apr 15, 2026
Dipna Pharmachem Limited Clarifies Significant Price Movement to BSE
Apr 08, 2026
Dipna Pharmachem Limited Receives BSE Trading Approval for 22.44 Lakh Equity Shares from Warrant Conversion
Jan 21, 2026
More news about Dipna Pharmachem
21
Jan 26
Dipna Pharmachem Responds to BSE Inquiry on Stock Price Movement, Cites Market-Driven Volatility
Dipna Pharmachem Limited responded to BSE's inquiry about significant stock price movement on January 21, 2026, clarifying that no price-sensitive information exists within the company. The firm confirmed compliance with SEBI LODR Regulations 2015 and attributed the price volatility to natural market forces rather than company-specific developments.
26
Nov 25
Dipna Pharmachem Reports 319% Surge in Net Profit for H1 FY2026, Raises Funds Through Convertible Warrants
Dipna Pharmachem Limited, a pharmaceutical trading company, reported a 319% increase in net profit to Rs 141.10 lakhs for H1 FY2026, despite an 18.85% decrease in total income to Rs 7,354.12 lakhs. The company raised Rs 1,893.31 lakhs through convertible warrants in September 2025. Dipna Pharmachem confirmed no deviations in fund utilization from its rights and preferential issues. Historical data shows fluctuating revenue but improving profitability trends since FY2021.
09
Sept 25
Dipna Pharmachem Allots 2.99 Crore Convertible Warrants at Rs 13.05 Each on Preferential Basis
Dipna Pharmachem Limited has approved the issuance of 2,98,74,000 convertible warrants at Rs 13.05 per warrant on a preferential basis to promoter and non-promoter categories. Each warrant is convertible into one equity share within 18 months of allotment. The company has collected 25% of the total consideration, amounting to Rs 9,74,63,925.00. The warrants were allotted to 23 individuals and entities, with Keyur Dipakkumar Shah and Ashok Dilipkumar Jain receiving the largest allocations.
Dipna Pharmachem
6.
99
-
0.
17
(-
2.
37
%)
1 Year Returns:
-68.57%
Industry Peers
Sun Pharmaceutical
1,789.90
(-
0.
37
%)
Divis Laboratories
6,533.00
(-
0.
31
%)
Torrent Pharmaceuticals
4,317.90
(-
0.
75
%)
Cipla
1,379.30
(-
0.
79
%)
Zydus Life Science
1,078.30
(-
1.
18
%)
Dr Reddys Laboratories
1,274.00
(-
1.
27
%)
Lupin
2,249.80
(-
0.
58
%)
Mankind Pharma
2,299.00
(-
0.
91
%)
Aurobindo Pharma
1,429.20
(-
0.
31
%)
Laurus Labs
1,382.60
(-
0.
42
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar